Login Register Cart 0
Perspective

奥替康唑:首个被批准用于治疗复发性外阴阴道念珠菌病的口服生物可利用选择性CYP51抑制剂

卷 30, 期 37, 2023

发表于: 03 March, 2023

页: [4170 - 4175] 页: 6

弟呕挨: 10.2174/0929867330666230220130024

摘要

奥特斯康唑于2022年4月获得美国FDA批准。它是第一个被批准用于治疗复发性外阴阴道念珠菌病的选择性和口服生物可利用的CYP51抑制剂。在此，我们描述了它的剂量，给药，化学结构，物理性质，合成，作用机制和药代动力学。

关键词: 抗真菌药物，作用机制，真菌羊毛甾醇去甲基酶，阴道炎，甾醇生物合成，奥替康唑。

« Previous Next »
[1]
Sobel, J.D. Vulvovaginal candidosis. Lancet, 2007, 369(9577), 1961-1971.
[http://dx.doi.org/10.1016/S0140-6736(07)60917-9] [PMID: 17560449]
[2]
Zhang, J.; Li, L.; Lv, Q.; Yan, L.; Wang, Y.; Jiang, Y. The fungal CYP51s: Their functions, structures, related drug resistance, and inhibitors. Front. Microbiol., 2019, 10, 691.
[http://dx.doi.org/10.3389/fmicb.2019.00691] [PMID: 31068906]
[3]
Chang, Y.L.; Yu, S.J.; Heitman, J.; Wellington, M.; Chen, Y.L. New facets of antifungal therapy. Virulence, 2017, 8(2), 222-236.
[http://dx.doi.org/10.1080/21505594.2016.1257457] [PMID: 27820668]
[4]
Hargrove, T.Y.; Friggeri, L.; Wawrzak, Z.; Qi, A.; Hoekstra, W.J.; Schotzinger, R.J.; York, J.D.; Guengerich, F.P.; Lepesheva, G.I. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. J. Biol. Chem., 2017, 292(16), 6728-6743.
[http://dx.doi.org/10.1074/jbc.M117.778308] [PMID: 28258218]
[5]
Brand, S.R.; Sobel, J.D.; Nyirjesy, P.; Ghannoum, M.A.; Schotzinger, R.J.; Degenhardt, T.P. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin. Infect. Dis., 2021, 73(7), e1518-e1524.
[http://dx.doi.org/10.1093/cid/ciaa1204] [PMID: 32818963]
[6]
Seiler, G.T.; Ostrosky-Zeichner, L. Investigational agents for the treatment of resistant yeasts and molds. Curr. Fungal Infect. Rep., 2021, 15(3), 104-115.
[http://dx.doi.org/10.1007/s12281-021-00419-5] [PMID: 34075318]
[7]
Stewart, A.G.; Paterson, D.L. How urgent is the need for new antifungals? Expert Opin. Pharmacother., 2021, 22(14), 1857-1870.
[http://dx.doi.org/10.1080/14656566.2021.1935868] [PMID: 34231434]
[8]
Sobel, J.D.; Nyirjesy, P. Oteseconazole: An advance in treatment of recurrent vulvovaginal candidiasis. Future Microbiol., 2021, 16(18), 1453-1461.
[http://dx.doi.org/10.2217/fmb-2021-0173] [PMID: 34783586]
[9]
Gupta, A.K.; Talukder, M.; Venkataraman, M. Review of the alternative therapies for onychomycosis and superficial fungal infections: Posaconazole, fosravuconazole, voriconazole, oteseconazole. Int. J. Dermatol., 2021, 61(12), 1431-1441.
[http://dx.doi.org/10.1111/ijd.15999] [PMID: 34882787]
[10]
Tortorano, A.M.; Prigitano, A.; Morroni, G.; Brescini, L.; Barchiesi, F. Candidemia: Evolution of drug resistance and novel therapeutic approaches. Infect. Drug Resist., 2021, 14, 5543-5553.
[http://dx.doi.org/10.2147/IDR.S274872] [PMID: 34984009]
[11]
Nyirjesy, P.; Brookhart, C.; Lazenby, G.; Schwebke, J.; Sobel, J.D. Vulvovaginal candidiasis: A review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines. Clin. Infect. Dis., 2022, 74(Suppl. 2), S162-S168.
[http://dx.doi.org/10.1093/cid/ciab1057] [PMID: 35416967]
[12]
Hoenigl, M.; Sprute, R.; Arastehfar, A.; Perfect, J.R.; Lass-Flörl, C.; Bellmann, R.; Prattes, J.; Thompson, G.R., III; Wiederhold, N.P.; Al Obaidi, M.M.; Willinger, B.; Arendrup, M.C.; Koehler, P.; Oliverio, M.; Egger, M.; Schwartz, I.S.; Cornely, O.A.; Pappas, P.G.; Krause, R. Invasive candidiasis: Investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin. Investig. Drugs, 2022, 31(8), 795-812.
[http://dx.doi.org/10.1080/13543784.2022.2086120] [PMID: 35657026]
[13]
Logan, A.; Wolfe, A.; Williamson, J.C. Antifungal resistance and the role of new therapeutic agents. Curr. Infect. Dis. Rep., 2022, 24(9), 105-116.
[http://dx.doi.org/10.1007/s11908-022-00782-5] [PMID: 35812838]
[14]
Martens, M.G.; Maximos, B.; Degenhardt, T.; Person, K.; Curelop, S.; Ghannoum, M.; Flynt, A.; Brand, S.R. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. Am. J. Obstet. Gynecol., 2022, 227(6), 880.e1-880.e11.
[http://dx.doi.org/10.1016/j.ajog.2022.07.023] [PMID: 35863457]
[15]
Wiederhold, N.P. Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J. Fungi, 2022, 8(8), 857.
[http://dx.doi.org/10.3390/jof8080857] [PMID: 36012845]
[16]
Hoekstra, W.J.; Garvey, E.P.; Moore, W.R.; Rafferty, S.W.; Yates, C.M.; Schotzinger, R.J. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg. Med. Chem. Lett., 2014, 24(15), 3455-3458.
[http://dx.doi.org/10.1016/j.bmcl.2014.05.068] [PMID: 24948565]
[17]
Hoekstra, W.J.; Yates, C.M. Mycovia Pharmaceuticals Inc, Antifungal compound process. US10836740B2, 2020.
[18]
Warrilow, A.G.S.; Parker, J.E.; Price, C.L.; Nes, W.D.; Garvey, E.P.; Hoekstra, W.J.; Schotzinger, R.J.; Kelly, D.E.; Kelly, S.L. The investigational drug VT-1129 is a highly potent inhibitor of cryptococcus species CYP51 but only weakly inhibits the human enzyme. Antimicrob. Agents Chemother., 2016, 60(8), 4530-4538.
[http://dx.doi.org/10.1128/AAC.00349-16] [PMID: 27161631]
[19]
Murphy, S.E.; Bicanic, T. Drug resistance and novel therapeutic approaches in invasive candidiasis. Front. Cell. Infect. Microbiol., 2021, 11, 759408.
[http://dx.doi.org/10.3389/fcimb.2021.759408] [PMID: 34970504]
[20]
Vanreppelen, G.; Nysten, J.; Baldewijns, S.; Sillen, M.; Donders, G.; Van Dijck, P. Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis. Trends Pharmacol. Sci., 2023, 44(1), 64-65.
[http://dx.doi.org/10.1016/j.tips.2022.10.004] [PMID: 36396498]
[21]
Nishimoto, A.T.; Whaley, S.G.; Wiederhold, N.P.; Zhang, Q.; Yates, C.M.; Hoekstra, W.J.; Schotzinger, R.J.; Garvey, E.P.; Rogers, P.D. Impact of the major candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob. Agents Chemother., 2019, 63(10), e01304-e01319.
[http://dx.doi.org/10.1128/AAC.01304-19] [PMID: 31383660]
[22]
Break, T.J.; Desai, J.V.; Natarajan, M.; Ferre, E.M.N.; Henderson, C.; Zelazny, A.M.; Siebenlist, U.; Hoekstra, W.J.; Schotzinger, R.J.; Garvey, E.P.; Lionakis, M.S. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans. J. Antimicrob. Chemother., 2018, 73(1), 151-155.
[http://dx.doi.org/10.1093/jac/dkx352] [PMID: 29040636]

Rights & Permissions Print Cite
Article Metrics
92
1
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy